Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis

Similar documents
TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

TB the basics. (Dr) Margaret (DHA) and John (INZ)

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

BRITISH BIOMEDICAL BULLETIN

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Fundamentals of Tuberculosis (TB)

INDEX CASE INFORMATION

Contact Investigation and Prevention in the USA

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director

TB infection control: overview and importance

Immune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela

Diagnosis and Treatment of Tuberculosis, 2011

TOG The Way Forward

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Treatment of Active Tuberculosis

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

TB Intensive San Antonio, Texas December 1-3, 2010

DR-TB Patient Treatment Log Book

Monica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale

Diagnosis and Medical Management of Latent TB Infection

TUBERCULOSIS. Pathogenesis and Transmission

New Tuberculosis Guidelines. Jason Stout, MD, MHS

Chapter 22. Pulmonary Infections

SMEAR MICROSCOPY AS SURROGATE FOR CULTURE DURING FOLLOW UP OF PULMONARY MDR-TB PATIENTS ON DOTS PLUS TREATMENT

Index No. All five (05) questions should be answered. All questions carry equal marks.

Northwestern Polytechnic University

Tuberculosis Populations at Risk

Screening and Treatment Recommendations for Persons Exposed to MDR TB

Tuberculosis Procedure ICPr016. Table of Contents

Revised National Tuberculosis Control Programme

Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria.

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore

PATHOLOGY & PATHOPHYSIOLOGY

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Characteristics of Mycobacterium

Patient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD

Treatment of Tuberculosis, 2017

Research Article The Pattern of Presentation and Prevalence of Tuberculosis in HIV-Seropositive Patients Seen at Benin City, Nigeria

Kenya Perspectives. Post-2015 Development Agenda. Tuberculosis

Original Article PYRAZINAMIDE THERAPY AND SEVERITY OF HAEMOPTYSIS. 2 Clotting Time 4.87 ± 1.46 Min. 3 Prothrombin Time ± Sec.

H D R I I N D U S S HEALTH-CARE DESIGN RESOURCE. Tuberculosis (TB) what you should know...

Surgery for MDR/XDR Tuberculosis

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

What is tuberculosis? What causes tuberculosis?

TB Program Management San Antonio, Texas November 5-7, 2008

Research Article. Saibal Moitra 1, Sukanta Sen 2 *, Prasanta Das 3, Mridula Bose 4. DOI: / ijrms

UC DavisTB Screening Requirement: How to submit your TB Health Assessment Form

My heart is racing. Managing Complex Cases. Case 1. Case 1

Communicable Disease Control Manual Chapter 4: Tuberculosis

TB: A Supplement to GP CLINICS

COHORT STUDY OF HIV POSITIVE AND HIV NEGATIVE TUBERCULOSIS in PENANG HOSPITAL: COMPARISON OF CLINICAL MANIFESTATIONS

Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation?

The diagnosis of active TB

Clinical Study Tuberculosis in Otorhinolaryngology: Clinical Presentation and Diagnostic Challenges

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Clinical Practice Guideline

"GUARDING AGAINST TUBERCULOSIS IN INSTITUTIONAL FACILITIES"

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Exploring the effectiveness of homoeopathy in children with cerebral palsy (CP)

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012

SWABCHA Fact Sheet: Tuberculosis (TB)

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Assessing the programmatic management of drug-resistant TB

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Pediatric TB Intensive Houston, Texas October 14, 2013

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats

"GUARDING AGAINST TUBERCULOSIS IN HEALTHCARE FACILITIES"

CMH Working Paper Series

All you need to know about Tuberculosis

2016 Annual Tuberculosis Report For Fresno County

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

Research Article Five-Year Assessment of Time of Sputum Smears Conversion and Outcome and Risk Factors of Tuberculosis Patients in Central Iran

Questions and Answers About

Treatment of Tuberculosis

Tuberculosis Tools: A Clinical Update

Management of MDR TB in special situations. Dr Sarabjit Chadha The Union

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

TUBERCULOSIS. What you need to know BECAUSE...CARING COMES NATURALLY TO US

Drug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction

The Respiratory System

Contact Investigation

TB in the Patient with HIV

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

Tuberculosis Intensive

New Entrant Screening and Latent TB Get screened and find out if you have TB infection before you develop TB disease!

Tuberculosis Pathogenesis

Dosage and Administration

Patient Information. Marital Status (Single, Married, Life Partner, Divorced, Widowed) CHIEF COMPLAINT

A Randomized Clinical Trial Comparing 6 EH vs 36H for TB Prevention in HIV-infected Adults in south India: Impact on Mortality

Information Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis

A Vietnamese woman with a 2-week history of cough

Profile of Tuberculosis Infection among Current HIV+ Patients at the Philippine General Hospital

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos

Transcription:

Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis Presenting author: Dr. Neha Sharma Authors: S. Sharma, RG Sharma, Chand K NMP Medical Research Institute, Jaipur & Sawali TB Sanitarium, Sikar Rajasthan, India

BACKGROUND OF THE STUDY TB is the Single largest infectious disease causing high mortality. Management is never simple endeavor, requires additional considerations in special situations like relapse, DR, MDR Chemotherapy is successful, but prolonged, costly and need to be directly observed. Otherwise relapse, drug resistance emerges. Toxicities are frequent Adjunctive treatment Garlic,, herbs, nutrient supplements with anti-tb drugs found to be effective Antimicrobial Effect of Chloroformic Garlic Extract on Mycobacterium Tuberculosis (Pakistan Journal of Biological Sciences 9 (12): 2381-2383, 2006)

REVIEW OF LITERATURE Effectiveness of homeopathy for upper respiratory tract complaints including allergies; lower respiratory tract complaints; or ear complaints Case reports highlighted the successful use in Pulmonary TB. Evaluation of Homoeopathic drugs in the treatment of tuberculosis Nehru H. M. C. and Hospital, New Delhi. Homeopathic treatment of multidrug resistant tuberculosis patients DP Rastogi 11 New Delhi, India Randomized trials: individualized homeopathy has an effect over placebo. The evidence, however, is not convincing because of methodological shortcomings and inconsistencies.

RESEARCH QUESTION Can Homeopathy improve sputum conversion in Relapsed Pulmonary Tuberculosis Patients following Conventional treatment. Can homeopathy improve the quality of life in Relapsed Pulmonary Tuberculosis Patients following Conventional treatment. Can Homeopathy improve clinical symptoms (haemoptysis, cough, chest pain, fever, and night sweating). Can Homeopathy bring about favorable modulation in weight, ESR and Hemoglobin.

SELECTION CRITERIA Inclusion Criteria 1. age of 18-60 years, 2. Relapse pulmonary tuberculosis* with acidfast bacilli smear positive by microscopy, using ZiehlNeelsen staining as recommended by WHO, Exclusion Criteria 1. Pregnancy, any concomitant disease I.e. diabetes mellitus, acute renal failure or 2. Infectious disease including TB/HIV and HIV positive, 3. Currently or taken any alternative therapies in past 6 months, *patients declared cured after one full course of Chemo and remaining well for some time become sputum smear + with radioactive lesion.

MEASUREMENT Clinical symptoms (haemoptysis, cough, chest pain, fever, and night sweating) Sputum AFB status by microscopy was recorded Weight Blood samples for Erythrocyte sedimentation rate and hemoglobin analyses Quality of life was assessed using SF 36

DESIGN OF STUDY- Clinical, Randomized,Double Blind Placebo Control Trial 52 patients randomized 26 Homeopathy 26 Placebo 2 months intervention Continued for 6 months of intervention Follow up for3 months 24 completed 23 completed

STRATEGIES Recruitment Randomization Blinding: Double blind study Placebo control Measurement approach: standard tools

INTERVENTION Anti-TB Chemotherapy Conventional treatment was based on daily regimen with single dose empty stomach for 8 months For 2 months streptomycin along with R, Z, E, H. followed by HERZ 1 month with H,E and R. <30 kg 30-50 kg >50 kg Time S 0.75 g 0-75 gm 1 gm 2 mo.daily INH 300 mg 300 mg 300 mg 8 mo R 300 mg 450 mg 600 mg 8 mo E 600 mg 800 mg 1000 mg 8 mo Z 800 mg 1200 mg 1500 mg Initial 2 mo

INTERVENTION Adjuvant therapy: HOMEOPATHY "It is more important to know what kind of person has a disease than what kind of disease a person has" - Sir William Osler Combinations of medicines ("complex homoeopathy") on the basis of conventional diagnosis and totality of symptoms. Build up a "symptom picture" of the patient. This is matched with a "drug picture" described in the homoeopathic Materia medica only one or two doses or a regular daily dose was used according to patient s constitution, temperament, and susceptibility.

Homeopathy: Drug picture PHOSPHORUS Talk, Indisposed to be silent Heat vital lack of Desire for cold drinks Haemoptysis Chest pain, lying on left Expectoration L froathy Numbness : toes Fever : Evening Perspiration : night LYCOPODIUM Company, desire for Confidence, want of self Appetite increased :afternoon Respiration : difficult, exertion after Cough : dry Chest pain, lying while

RESULTS Baseline characteristics of relapsed TB patients treated with homeopathy or placebo Characteristic Age yrs, mean ± SD Sex M/F,, no. Educational status, literate Work status Farming Industries Construction Unemployed Homeopathy group (N=24) 30.17 ± 4.94 14/10 70% 50% 28.25% 18.75% 3% Placebo group (N=23) 31.13 ± 4.87 16/7 57.15 % 43.75% 31.25 21% 4 %

RESULTS Comparing Homeo and placebo at 0,2,8,11 mo. parameter 0 mo. H/P 2 mo. H/P ( p<) p 8 mo. H/P ( p<) p 11 mo. H/P ( p<) p Sputum(-) 0/0 19/11(0.02) 21/11 (0.004) 21/10(0.002) Haemoptysis(+) 22/ 22 1/14 (0.000) 1/10 (0.002) 1/10(0.002) Cough(Severe) 24/23 3/23(0.000) 3/3 3/14(0.001) Fever (freq) 18/23 3/11(0.009) 4/9 3/11(0.009) Night sweat (+) 21/22 2/12(0.001) 1/11 (0.001) 2/12(0.000) Chest pain (Mean ±SD) 7.46±1.7/ 7.83±1.5 5.75± 1.39/ 6.56 ± 1.44 4.04±1.04 5.17±1.19 1.19 (0.005) 2.75±1.11 4.52±1.95 (0.002)

RESULTS Comparing Homeo and placebo at 0,2,8,11 mo Parameter Breathless-ness Weight/kg Hb gm% ESR Mm/hr 0 mo. H/P 7.67±1.3/ 7.83±1.2 41.62±4.58/ 4.58/ 40.39±4.63 4.63 8.88±1.29/ 9.08±1.19 75.46±8.73/ 74.21±6.71 2 mo. H/P 5.62±0.57/ 7.00±1.83 ( p<0.02) p 43.00±4.30/ 4.30/ 39.65± 4.42 ( p<0.01) p 9.75±1.26/ 9.16±1.24 1.24 49.58±6.76/ 66.17±9.61 ( p<0.001) p 8 mo. H/P 4.29±0.46/ 6.30±2.30 (p< 0.002) 46.21±3.23/ 41.04±4.26 4.26 (p< < 0.000) 11.12±0.85/ 9.21±0.80 (p< < 0.000) 11.33±3.79/ 3.79/ 37.17±27.64 (p< < 0.001) 11 mo. H/P 3.42±1.32/ 5.48±2.86 (p< < 0.01) 50.17±3.64/ 41.48±4.06 4.06 (p< < 0.000) 11.87±0.80/ 9.95±1.46 (p< < 0.000) 9.87±1.57/ 36.91±30.96 30.96 (p< < 0.05)

RESULTS Quality of life SF 36 domain Physical function Body pain General health Vitality/energy Social function Mental health Role limitation physical Role limitation emotional Homeopathy 80.33±8.72 8.72 74.42±10.34 87.50±8.52 8.52 79.83±15.99 84.87±7.99 7.99 79.83±10.95 80.58±7.36 85.04±8.89 8.89 Placebo p value 56.30± 13.76 0.000 63.74±7.10 7.10 0.000 69.36±18.43 0.000 65.69±12.60 0.000 72.22±10.63 0.000 62.30± 14.44 0.000 64.52±12.71 0.000 58.61±14.38 14.38 0.000

Change in the symptoms change in symptoms 30 25 20 15 0 2 8 11 10 5 0 H hemopt ysis P Hemopt ysis H cough P cough

Change in the symptoms change in symptoms 25 20 15 10 0 2 8 11 5 0 H f ever P f ever H nigh swaet ing P Night swaet ung

Change in weight and sputum wei ght gai n and sputum conevr si on 60 50 40 30 20 H Wei ght P wei ght H sputum P sputum 10 0 0 2 8 11 months

Change in the Hematology 80 70 60 50 40 30 H ESR P ESR H HB P HB 20 10 0 0 2 8 11

Comparing quality of life change in quality of life score of SF 36 100 90 80 70 60 50 40 30 20 10 0 1 2 3 4 5 6 7 8 domain of SF 36 Homeopathy group Placebo group 1-physical function, 2-body pain, 3-general health, 4-vitality/energy, 5-social functioning, 6- mental health, 7-role limitation physical, 8-role limitation emotional.

DISCUSSION Homeopathy supplementation has a significant and favorable effect on weight gain, sputum conversion,, and reduction of symptoms like cough. Reduced cough and increased Mycobacterial clearance in Sputum observed at 2 month. There wasn t t any significant side effect or worsening symptoms were recorded.

STREANGTH OF STUDY Homeopathy in the form in which it is commonly practiced rather than in a form specially modified for clinical trials. More than one homeopath, as negative result might have been attributed to lack of competence of a single therapist. Study design Good adherence

WEAKNESS OF STUDY Limitations of sputum culture of the study population Shorter follow up period of 3 months Study design would have been improved by conducting sample size calculation, by stratifying by tuberculosis conditions, and by choosing outcome measures (or modifying those used) to be more sensitive to change.

WHAT S NEXT? Resistance or multi drug resistance Longer follow up Comparing different approach of Homeopathy

Questions? Comments? NMP Medical Research Institute Dr. Neha Sharma 59- A Mahadev Nagar, Dundlod House Bais Godam, Jaipur, Rajasthan, India 91-09829395513 nehabhatra@yahoo.com